Mimma Rizzo

3.0k total citations
78 papers, 1.1k citations indexed

About

Mimma Rizzo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Mimma Rizzo has authored 78 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 29 papers in Molecular Biology. Recurrent topics in Mimma Rizzo's work include Renal cell carcinoma treatment (47 papers), Cancer Genomics and Diagnostics (24 papers) and Renal and related cancers (22 papers). Mimma Rizzo is often cited by papers focused on Renal cell carcinoma treatment (47 papers), Cancer Genomics and Diagnostics (24 papers) and Renal and related cancers (22 papers). Mimma Rizzo collaborates with scholars based in Italy, United States and Spain. Mimma Rizzo's co-authors include Camillo Porta, Giacomo Cartenì, Giuseppe Di Lorenzo, Riccardo Autorino, Francesco Massari, Michele Aieta, Sabino De Placido, Laura Cosmai, A. Gonnella and Corrado Ficorella and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Mimma Rizzo

71 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mimma Rizzo Italy	17	696	484	428	333	113	78	1.1k
Florian Kocher Austria	18	357 0.5×	215 0.4×	498 1.2×	160 0.5×	83 0.7×	72	990
Jessica Read United Kingdom	9	514 0.7×	428 0.9×	733 1.7×	165 0.5×	56 0.5×	11	1.6k
S. Srinivas United States	13	527 0.8×	410 0.8×	282 0.7×	264 0.8×	137 1.2×	38	816
Cristian Lolli Italy	19	761 1.1×	274 0.6×	578 1.4×	331 1.0×	50 0.4×	88	1.4k
Ronald Tutrone United States	21	1.1k 1.6×	426 0.9×	226 0.5×	398 1.2×	43 0.4×	111	1.7k
Philippe Montcuquet France	16	332 0.5×	247 0.5×	581 1.4×	248 0.7×	100 0.9×	38	919
Shefali Chopra United States	14	547 0.8×	426 0.9×	324 0.8×	278 0.8×	50 0.4×	57	1.1k
Marina D. Kaymakcalan United States	15	374 0.5×	261 0.5×	423 1.0×	217 0.7×	225 2.0×	32	912
Varun Monga United States	19	355 0.5×	283 0.6×	372 0.9×	134 0.4×	57 0.5×	81	1.1k
Yuanjue Sun China	18	399 0.6×	315 0.7×	426 1.0×	138 0.4×	132 1.2×	41	937

Countries citing papers authored by Mimma Rizzo

Since Specialization

Citations

This map shows the geographic impact of Mimma Rizzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mimma Rizzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mimma Rizzo more than expected).

Fields of papers citing papers by Mimma Rizzo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mimma Rizzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mimma Rizzo. The network helps show where Mimma Rizzo may publish in the future.

Co-authorship network of co-authors of Mimma Rizzo

This figure shows the co-authorship network connecting the top 25 collaborators of Mimma Rizzo. A scholar is included among the top collaborators of Mimma Rizzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mimma Rizzo. Mimma Rizzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Campione, Marina, Sara Elena Rebuzzi, Lucia Fratino, et al.. (2025). Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy. Technology in Cancer Research & Treatment. 24. 2244058514–2244058514. 1 indexed citations

Cafforio, Paola, et al.. (2024). Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma. Medicina. 60(4). 585–585. 2 indexed citations

Re, Marzia Del, Stefania Crucitta, Nicole Brighi, et al.. (2024). Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer. Clinical Genitourinary Cancer. 22(5). 102147–102147. 1 indexed citations

Cafforio, Paola, et al.. (2024). Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective. Therapeutic Advances in Medical Oncology. 16. 12743236–12743236. 2 indexed citations

Iacovelli, Roberto, Emanuela Fantinel, Davide Bimbatti, et al.. (2024). Efficacy of perioperative pembrolizumab treatment in patients with resectable metastases from kidney cancer: The PE-PE study.. Journal of Clinical Oncology. 42(4_suppl). TPS495–TPS495.

Bogani, Giorgio, Michela Cinquini, Diego Signorelli, et al.. (2023). A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study. Critical Reviews in Oncology/Hematology. 187. 104016–104016. 15 indexed citations

Tommasi, Stefania, et al.. (2023). Concomitant Immunotherapy and Metastasis-Directed Radiotherapy in Upper Tract Urothelial Carcinoma: A Biomarker-Driven, Original, Case-Based Proof-of-Concept Study. Journal of Clinical Medicine. 12(24). 7761–7761. 3 indexed citations

Bersanelli, Melissa, Letizia Gnetti, Francesco Paolo Pilato, et al.. (2023). Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity. SHILAP Revista de lepidopterología. 4(4). 743–756.

Porta, Camillo, Vittorio Ferrari, Paolo Andrea Zucali, et al.. (2022). Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The “retry” study from the Italian Group of Onco-Nephrology (G.I.O.N.). 6(3). 107–114. 1 indexed citations

10.

Santoni, Matteo, Francesco Massari, Marc Matrana, et al.. (2022). Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. European Journal of Cancer. 172. 191–198. 15 indexed citations

11.

Basso, Umberto, Giuseppe Procopio, Giuseppe Fornarini, et al.. (2021). Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16). Oncology. 99(12). 747–755. 2 indexed citations

12.

Francolini, Giulio, Simona Borghesi, Sergio Fersino, et al.. (2021). Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: Trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Critical Reviews in Oncology/Hematology. 159. 103235–103235. 7 indexed citations

13.

Santoni, Matteo, Francesco Piva, Camillo Porta, et al.. (2020). Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. Clinical Genitourinary Cancer. 19(2). e84–e91. 20 indexed citations

14.

Massari, Francesco, Veronica Mollica, Alessandro Rizzo, et al.. (2020). Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opinion on Drug Safety. 19(10). 1329–1338. 67 indexed citations

15.

Incorvaia, Lorena, Daniele Fanale, Giuseppe Badalamenti, et al.. (2020). Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. OncoImmunology. 9(1). 1832348–1832348. 55 indexed citations

16.

Porta, Camillo, Patrizia Giannatempo, Mimma Rizzo, et al.. (2020). An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas. Expert Opinion on Pharmacotherapy. 21(18). 2199–2204. 4 indexed citations

17.

Tucci, Marcello, Orazio Caffo, Consuelo Buttigliero, et al.. (2019). Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. Cancer Treatment Reviews. 74. 35–42. 22 indexed citations

18.

Porta, Camillo & Mimma Rizzo. (2019). Immune-based combination therapy for metastatic kidney cancer. Nature Reviews Nephrology. 15(6). 324–325. 1 indexed citations

19.

Passardi, Alessandro, Mimma Rizzo, Francesca Maines, et al.. (2017). Optimisation and validation of a remote monitoring system (Onco-TreC) for home-based management of oral anticancer therapies: an Italian multicentre feasibility study. BMJ Open. 7(5). e014617–e014617. 22 indexed citations

20.

Lorenzo, Giuseppe Di, Riccardo Autorino, Giacomo Cartenì, et al.. (2009). Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Annals of Oncology. 20(9). 1535–1542. 169 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact